Xtl Biopharmaceuticals (XTLB) Accumulated Expenses (2022 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Accumulated Expenses for 4 consecutive years, with $129000.0 the latest figure, recorded in Q4 2025.

• Quarterly Accumulated Expenses fell 73.78% year-over-year to $129000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $129000.0 (down 73.78% YoY) and the FY2025 annual result came in at $129000.0, down 73.78% from the prior year.
• Accumulated Expenses fell to $129000.0 in Q4 2025 per XTLB's latest filing, from $492000.0 in the prior quarter.
• Over the last five years, Accumulated Expenses for XTLB reached as high as $492000.0 in Q4 2024 and fell as low as $129000.0 in Q4 2025.
• A 4-year average of $252750.0 and a median of $195000.0 in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses surged 140.0% — and 2025, when it plunged 73.78%.
• Year by year, Accumulated Expenses stood at $185000.0 in 2022, then increased by 10.81% to $205000.0 in 2023, then jumped by 140.0% to $492000.0 in 2024, then tumbled by 73.78% to $129000.0 in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $129000.0, $492000.0, and $205000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.